Fintel reports that on March 13, 2025, Chardan Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Neutral to Buy. As of March 4, 2025, the average one-year price target for CervoMed is ...

Fintel reports that on March 13, 2025, Jones Trading upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of March 4, 2025, the average one-year price target for CervoMed is $20.66 ...

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies ...

Participants on New Capsules showed a lower increase in dementia severity than those on Old Capsules. Chardan upgraded CervoMed to Buy, citing compelling 16-week extension data. Get a Year of Fast, ...

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. CervoMed ( (CRVO) ) has provided an announcement.

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how CervoMed Inc. (NASDAQ:CRVO) compares to the other top short squeeze stocks that ...

CervoMed (NASDAQ:CRVO – Get Free Report) had its target price lifted by equities research analysts at Canaccord Genuity Group from $12.00 to $21.00 in a report issued on Tuesday,Benzinga reports. The ...

While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, ...